Who cares. The fact of the matter is the stock is at .0004, down 90% in 2 months, the share count has tripled in just two months and there is no sign they are close to getting approval despite claiming the product would be launched by the end of the 2nd qtr.
Those are the relevant issues. Everything else is irrelevant.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.